Abstract
During the 2018–2020 Ebola virus disease (EVD) outbreak in North Kivu province in the Democratic Republic of Congo, EVD was diagnosed in a patient who had received the recombinant vesicular stomatitis virus–based vaccine expressing a ZEBOV glycoprotein (rVSV-ZEBOV) (Merck). His treatment included an Ebola virus (EBOV)–specific monoclonal antibody (mAb114), and he recovered within 14 days. However, 6 months later, he presented again with severe EVD-like illness and EBOV viremia, and he died. We initiated epidemiologic and genomic investigations that showed that the patient had had a relapse of acute EVD that led to a transmission chain resulting in 91 cases across six health zones over 4 months. (Funded by the Bill and Melinda Gates Foundation and others.)
Original language | English (US) |
---|---|
Pages (from-to) | 1240-1247 |
Number of pages | 8 |
Journal | New England Journal of Medicine |
Volume | 384 |
Issue number | 13 |
DOIs | |
State | Published - Apr 1 2021 |
ASJC Scopus subject areas
- Medicine(all)